9.4 HDFN Treatment & Prevention

9.4 HDFN Treatment & Prevention

Quick Answer: Severe fetal anemia detected by MCA-PSV or cordocentesis is treated with intrauterine transfusion (IUT) using fresh, irradiated, CMV-safe, hemoglobin S-negative, antigen-negative red cells crossmatched against maternal serum. After birth, phototherapy and intravenous immunoglobulin (IVIG) reduce the need for double-volume exchange transfusion, which is reserved for severe unresponsive hyperbilirubinemia or significant anemia at birth. Prevention centers on Rh immune globulin (RhIG), which suppresses maternal anti-D formation but does not prevent alloimmunization to other red cell antigens.

Intrauterine Transfusion (IUT)

When MCA-PSV reaches or exceeds 1.5 MoM, or hydrops is present, cordocentesis confirms fetal anemia and the fetus may proceed directly to intrauterine transfusion. The intravascular route, injecting red cells directly into the umbilical vein under continuous ultrasound guidance, is the preferred technique because it is more predictable and allows immediate post-transfusion hematocrit sampling; the intraperitoneal route is used less often (for example, at very early gestational ages or when vascular access is technically difficult) and relies on slower absorption through the subdiaphragmatic lymphatics.

Red cells selected for IUT must meet specialist-level component requirements:

• Group O (or otherwise ABO-compatible with the mother) and negative for the antigen corresponding to the maternal antibody
• Crossmatched against maternal serum/plasma, not the fetus, because the antibody responsible for HDFN is maternal in origin
• Irradiated, to prevent transfusion-associated graft-versus-host disease in the immunologically immature fetus
• CMV-seronegative or leukoreduced, to reduce transfusion-transmitted cytomegalovirus risk
• Hemoglobin S-negative
• Fresh (generally less than 5-7 days old), to minimize extracellular potassium and preserve ATP/2,3-DPG, given the direct intravascular route and small fetal blood volume
• Concentrated to a high hematocrit (approximately 75-85%), to deliver an adequate hematocrit rise while minimizing infused volume and avoiding fetal volume overload

The transfusion goal is typically to raise the fetal hematocrit to about 40-50%. IUT is usually repeated every 2-4 weeks until the fetus reaches a gestational age (commonly around 35 weeks) at which delivery is safer than continued in-utero management; stable pregnancies are typically delivered around 37-38 weeks. In select severe, early cases, maternal IVIG is sometimes used as an adjunct to delay the need for the first IUT.

Postnatal Treatment

After birth, management is guided by the degree of hyperbilirubinemia and anemia:

1. Phototherapy is first-line treatment for neonatal hyperbilirubinemia; it photoisomerizes unconjugated bilirubin in the skin into water-soluble forms that can be excreted without hepatic conjugation.
2. IVIG can be given to reduce ongoing hemolysis by blocking Fc receptors on splenic macrophages, decreasing destruction of antibody-coated red cells and reducing the likelihood of needing exchange transfusion.
3. Double-volume exchange transfusion (DVET) is reserved for severe hyperbilirubinemia unresponsive to intensive phototherapy, a rapidly rising bilirubin despite treatment, or significant anemia/hydrops at birth. The exchange volume is calculated as twice the neonate's blood volume (approximately 160 mL/kg), which replaces roughly 85-90% of the infant's circulating red cells and removes a substantial portion of circulating bilirubin and antibody, though bilirubin typically rebounds afterward as it re-equilibrates from the extravascular space.
4. Simple top-up (small-volume) transfusion is used for isolated anemia without dangerous hyperbilirubinemia, including late-onset anemia, which can develop weeks after birth from ongoing low-grade hemolysis or transfusion-related marrow suppression after IUT, and requires continued monitoring after discharge.

Components for exchange transfusion mirror IUT requirements: reconstituted whole blood (red cells plus plasma, adjusted to a hematocrit of roughly 40-50%), less than 5-7 days old, irradiated, CMV-safe, hemoglobin S-negative, negative for the relevant antigen, crossmatched preferentially against maternal serum (or against both maternal and infant serum if maternal serum is unavailable), and warmed before infusion to avoid hypothermia and cardiac arrhythmia.

Prevention: Rh Immune Globulin (RhIG)

RhIG is passive anti-D immunoglobulin given to D-negative, non-alloimmunized pregnant patients to prevent primary anti-D sensitization; the leading proposed mechanism is rapid clearance of D-positive fetal cells from the maternal circulation before the maternal immune system mounts a durable antibody response. Standard practice includes:

• A 300 mcg (1500 IU) dose at 28 weeks gestation, assuming the antibody screen remains negative
• A 300 mcg dose within 72 hours after delivery if the infant is confirmed D-positive
• Additional doses after any potentially sensitizing event later in pregnancy (amniocentesis, chorionic villus sampling, external cephalic version, abdominal trauma, antepartum hemorrhage); a reduced 50 mcg microdose is generally sufficient for events at or before 12 weeks gestation, when fetal blood volume is minimal

A standard 300 mcg dose covers exposure to approximately 30 mL of fetal whole blood (15 mL of fetal red cells). When a large fetomaternal hemorrhage (FMH) is suspected, especially after delivery or trauma, a qualitative rosette test screens for excess fetal cells; if positive, the Kleihauer-Betke acid elution test or flow cytometry quantifies the hemorrhage so the laboratory can calculate the number of additional RhIG vials required (the calculated dose is always rounded up).

RhIG has reduced RhD alloimmunization rates from roughly 13-16% to under 1% in appropriately managed pregnancies, one of the most effective prevention programs in transfusion medicine. It is critical to recognize its limits: RhIG contains only anti-D and provides no protection against alloimmunization to other clinically significant antigens such as c, E, K, Fya, or Jka, for which no equivalent prophylactic product exists.